Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pharmacokinetic and therapeutic equivalence of Zelapar and Eldepryl

Oct. 27, 1998

New serotonergic agents in development at ADIR for CNS disorders

Oct. 27, 1998

Yamanouchi discloses 5-HT2C receptor agonists with high potency and selectivity

Oct. 27, 1998

Korean research institute develops new NMDA receptor antagonists

Oct. 27, 1998

Agents for schizophrenia from Yoshitomi typified by Y-36074

Oct. 27, 1998

Dainippon will initiate European development of antipsychotic drug candidate

Oct. 27, 1998

Sublingual apomorphine safe and effective in PD patients with motor fluctuations

Oct. 26, 1998

Transdermal selegiline as monotherapy in mild to moderate Parkinson's disease

Oct. 26, 1998

Transdermal D2 agonist therapy with N-0923 safe and effective in PD

Oct. 26, 1998

Metabasis Therapeutics seeks partner for development of anticonvulsant

Oct. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...